Sectoral Asset Management
MONTREAL, A8files as SECTORAL ASSET MANAGEMENT INC
$143m in 82 US stocks at the end of 30 June 2026. The top 10 are 39.6% of the money. It changed about 29.2% of the portfolio this quarter.
Value
$143m
Stocks
82
Top 10 share
39.6%
Turnover
29.2%
What changed this quarter
New
Bought for the first time this quarter.
- Oruka TherapeuticsORKA2.8% of the fund
- Definium TherapeuticsDFTX2.6% of the fund
- iRhythm HoldingsIRTC2.2% of the fund
- Avalo TherapeuticsAVTX1.5% of the fund
- Crescent BiopharmaCBIO1.5% of the fund
- Pulse BiosciencesPLSE1.3% of the fund
- Alphatec HoldingsATEC1.1% of the fund
- TransMedics GroupTMDX1.0% of the fund
- CVS HealthCVS0.9% of the fund
- CenteneCNC0.5% of the fund
- Ascendis Pharma A/SASND0.5% of the fund
- HumanaHUM0.3% of the fund
- Tempus AITEM0.2% of the fund
- Corbus Pharmaceuticals HoldingsCRBP0.1% of the fund
- enGene TherapeuticsENGN<0.1% of the fund
Added
Bought more of a stock they already held.
- Biontech SEBNTX2.7% of the fund+89%
- DexcomDXCM2.4% of the fund+118%
- Arcus BiosciencesRCUS2.4% of the fund+146%
- Summit TherapeuticsSMMT2.2% of the fund+216%
- ArriVent BioPharmaAVBP1.9% of the fund+163%
- InsmedINSM1.7% of the fund+18%
- Tectonic TherapeuticTECX1.7% of the fund+273%
- Intuitive SurgicalISRG1.6% of the fund+11%
- ImmaticsIMTX1.6% of the fund+237%
- StrykerSYK1.6% of the fund+21%
- Roivant SciencesROIV1.5% of the fund+88%
- Iqvia HoldingsIQV1.5% of the fund+31%
- Boston ScientificBSX1.1% of the fund+4%
- CytokineticsCYTK1.0% of the fund+124%
- Cogent BiosciencesCOGT0.7% of the fund+21%
- Tarsus PharmaceuticalsTARS0.6% of the fund+18%
- PTC TherapeuticsPTCT0.4% of the fund+12%
Cut
Sold some of their stake.
- UnitedHealth GroupUNH3.8% of the fund-12%
- Vertex PharmaceuticalsVRTX1.9% of the fund-22%
- Argenx SEARGX1.8% of the fund-21%
- Gilead SciencesGILD1.8% of the fund-25%
- Abbott LaboratoriesABT1.1% of the fund-29%
- Regeneron PharmaceuticalsREGN0.9% of the fund-26%
- Edwards LifesciencesEW0.9% of the fund-14%
- Trevi TherapeuticsTRVI0.9% of the fund-12%
- United TherapeuticsUTHR0.5% of the fund-20%
- Hinge HealthHNGE0.5% of the fund-29%
- Nektar TherapeuticsNKTR0.5% of the fund-7%
- Privia Health GroupPRVA0.4% of the fund-11%
- Mineralys TherapeuticsMLYS0.3% of the fund-54%
- Syndax PharmaceuticalsSNDX0.2% of the fund-51%
- BridgeBio PharmaBBIO0.2% of the fund-49%
- ARS PharmaceuticalsSPRY0.2% of the fund-62%
- Structure TherapeuticsGPCR0.2% of the fund-69%
Sold out
Sold their entire stake.
- EvommuneEVMN-100%
- Rapport TherapeuticsRAPP-100%
- Boundless BioBOLD-100%
- Ascendis Pharma A/SASND-100%
- uniQureQURE-100%
- Alignment HealthcareALHC-100%
- RadNetRDNT-100%
- Inspire Medical SystemsINSP-100%
- Neurocrine BiosciencesNBIX-100%
- Omada HealthOMDA-100%
Holdings
- Biontech SEBNTX
- Share
- 2.7%
- Value
- $4m
- Shares
- 41,869
+89%
- Argenx SEARGX
- Share
- 1.8%
- Value
- $3m
- Shares
- 2,831
-21%
- Beone MedicinesONC
- Share
- 0.4%
- Value
- $532,894
- Shares
- 1,870
Held
- Abivax SAABVX
- Share
- 0.2%
- Value
- $311,828
- Shares
- 2,340
Held
- Structure TherapeuticsGPCR
- Share
- 0.2%
- Value
- $232,123
- Shares
- 4,325
-69%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Contineum TherapeuticsCTNM | 8.3% | $12m | 727,587 | Held |
| Shoulder InnovationsSI | 6.1% | $9m | 430,407 | Held |
| Eli LillyLLY | 5.3% | $8m | 6,354 | Held |
| UnitedHealth GroupUNH | 3.8% | $6m | 13,235 | -12% |
| Johnson & JohnsonJNJ | 3.2% | $5m | 18,218 | Held |
| Oruka TherapeuticsORKA | 2.8% | $4m | 41,987 | New |
| Biontech SEBNTX | 2.7% | $4m | 41,869 | +89% |
| Definium TherapeuticsDFTX | 2.6% | $4m | 78,310 | New |
| DexcomDXCM | 2.4% | $3m | 50,756 | +118% |
| Arcus BiosciencesRCUS | 2.4% | $3m | 110,870 | +146% |
| AmgenAMGN | 2.3% | $3m | 9,210 | Held |
| Summit TherapeuticsSMMT | 2.2% | $3m | 220,180 | +216% |
| iRhythm HoldingsIRTC | 2.2% | $3m | 26,070 | New |
| AbbVieABBV | 2.1% | $3m | 12,200 | Held |
| MerckMRK | 1.9% | $3m | 21,480 | Held |
| ArriVent BioPharmaAVBP | 1.9% | $3m | 79,043 | +163% |
| Vertex PharmaceuticalsVRTX | 1.9% | $3m | 5,432 | -22% |
| Argenx SEARGX | 1.8% | $3m | 2,831 | -21% |
| Gilead SciencesGILD | 1.8% | $3m | 20,620 | -25% |
| InsmedINSM | 1.7% | $2m | 23,216 | +18% |
| Tectonic TherapeuticTECX | 1.7% | $2m | 71,009 | +273% |
| Intuitive SurgicalISRG | 1.6% | $2m | 5,850 | +11% |
| ImmaticsIMTX | 1.6% | $2m | 224,928 | +237% |
| StrykerSYK | 1.6% | $2m | 7,129 | +21% |
| Avalo TherapeuticsAVTX | 1.5% | $2m | 119,923 | New |
| Crescent BiopharmaCBIO | 1.5% | $2m | 121,300 | New |
| Roivant SciencesROIV | 1.5% | $2m | 61,100 | +88% |
| Iqvia HoldingsIQV | 1.5% | $2m | 10,848 | +31% |
| Pulse BiosciencesPLSE | 1.3% | $2m | 67,895 | New |
| DanaherDHR | 1.3% | $2m | 9,597 | Held |
| Thermo Fisher ScientificTMO | 1.2% | $2m | 3,508 | Held |
| Abbott LaboratoriesABT | 1.1% | $2m | 18,080 | -29% |
| Alphatec HoldingsATEC | 1.1% | $2m | 185,900 | New |
| Boston ScientificBSX | 1.1% | $2m | 36,330 | +4% |
| TransMedics GroupTMDX | 1.0% | $1m | 21,950 | New |
| CytokineticsCYTK | 1.0% | $1m | 16,330 | +124% |
| Regeneron PharmaceuticalsREGN | 0.9% | $1m | 2,169 | -26% |
| CVS HealthCVS | 0.9% | $1m | 13,000 | New |
| Edwards LifesciencesEW | 0.9% | $1m | 14,826 | -14% |
| Trevi TherapeuticsTRVI | 0.9% | $1m | 65,596 | -12% |
| Bristol-Myers SquibbBMY | 0.9% | $1m | 21,150 | Held |
| Vera TherapeuticsVERA | 0.8% | $1m | 25,573 | Held |
| Cogent BiosciencesCOGT | 0.7% | $1m | 26,740 | +21% |
| MedtronicMDT | 0.6% | $876,345 | 11,100 | Held |
| Tarsus PharmaceuticalsTARS | 0.6% | $836,158 | 13,285 | +18% |
| Kura OncologyKURA | 0.5% | $784,136 | 71,480 | Held |
| CenteneCNC | 0.5% | $770,280 | 12,000 | New |
| United TherapeuticsUTHR | 0.5% | $742,307 | 1,370 | -20% |
| Hinge HealthHNGE | 0.5% | $725,752 | 8,744 | -29% |
| Nektar TherapeuticsNKTR | 0.5% | $705,849 | 10,111 | -7% |
| Alnylam PharmaceuticalsALNY | 0.5% | $695,379 | 2,310 | Held |
| Ascendis Pharma A/SASND | 0.5% | $685,470 | 2,570 | New |
| PfizerPFE | 0.5% | $662,200 | 27,500 | Held |
| ArdelyxARDX | 0.4% | $624,209 | 122,394 | Held |
| Privia Health GroupPRVA | 0.4% | $621,019 | 24,136 | -11% |
| PTC TherapeuticsPTCT | 0.4% | $609,328 | 7,470 | +12% |
| Ionis PharmaceuticalsIONS | 0.4% | $570,888 | 7,200 | Held |
| AgomAb Therapeutics NVAGMB | 0.4% | $564,630 | 43,500 | Held |
| Biomarin PharmaceuticalBMRN | 0.4% | $540,729 | 9,450 | Held |
| Beone MedicinesONC | 0.4% | $532,894 | 1,870 | Held |
| HumanaHUM | 0.3% | $497,299 | 1,250 | New |
| Jazz PharmaceuticalsJAZZ | 0.3% | $421,698 | 1,750 | Held |
| Royalty PharmaRPRX | 0.3% | $403,704 | 7,200 | Held |
| BiogenBIIB | 0.3% | $399,711 | 1,850 | Held |
| Mineralys TherapeuticsMLYS | 0.3% | $392,964 | 14,565 | -54% |
| IlluminaILMN | 0.3% | $374,870 | 2,132 | Held |
| Axsome TherapeuticsAXSM | 0.3% | $367,155 | 1,500 | Held |
| Syndax PharmaceuticalsSNDX | 0.2% | $342,765 | 15,680 | -51% |
| Revolution MedicinesRVMD | 0.2% | $342,722 | 1,830 | Held |
| Abivax SAABVX | 0.2% | $311,828 | 2,340 | Held |
| BridgeBio PharmaBBIO | 0.2% | $305,368 | 4,100 | -49% |
| ModernaMRNA | 0.2% | $304,631 | 4,350 | Held |
| Guardant HealthGH | 0.2% | $297,059 | 1,980 | Held |
| IncyteINCY | 0.2% | $266,396 | 2,350 | Held |
| Oric PharmaceuticalsORIC | 0.2% | $254,505 | 23,500 | Held |
| ARS PharmaceuticalsSPRY | 0.2% | $239,499 | 29,900 | -62% |
| Structure TherapeuticsGPCR | 0.2% | $232,123 | 4,325 | -69% |
| Medpace HoldingsMEDP | 0.2% | $227,724 | 430 | Held |
| Tempus AITEM | 0.2% | $224,768 | 3,880 | New |
| Corbus Pharmaceuticals HoldingsCRBP | 0.1% | $187,600 | 20,000 | New |
| Palisade BIOPALI | 0.1% | $183,920 | 88,000 | Held |
| enGene TherapeuticsENGN | <0.1% | $37,541 | 21,700 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is down 5.4% since 30 June 2025.
Where the money is
Health care94.0%
Technology0.7%
Other5.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.